<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04095182</url>
  </required_header>
  <id_info>
    <org_study_id>WID-ESL18-P1</org_study_id>
    <nct_id>NCT04095182</nct_id>
  </id_info>
  <brief_title>Clinical Trial for Zebinix (Eslicarbazepine Acetate) in Healthy Korean and Caucasian Adult</brief_title>
  <official_title>A Dose Randomized, Double-blind, Placebo Controlled, Single and Multiple Dosing, Dose-escalation Phase I Clinical Trial to Investigate the Safety, Tolerability and Pharmacokinetic Characteristics of Zebinix (Eslicarbazepine Acetate) After Oral Administration in Healthy Korean and Caucasian Adult Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Whanin Pharmaceutical Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Whanin Pharmaceutical Company</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      A dose randomized, double-blind, placebo controlled, single and multiple dosing,
      dose-escalation phase I clinical trial to investigate the safety, tolerability and
      pharmacokinetic characteristics of Zebinix (Eslicarbazepine acetate) after oral
      administration in healthy Korean and Caucasian adult subjects
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 22, 2019</start_date>
  <completion_date type="Actual">December 16, 2019</completion_date>
  <primary_completion_date type="Actual">December 16, 2019</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time of maximum observed drug concentration (Tmax)</measure>
    <time_frame>'Day 1' 0(pre-dose), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 48, 72, 96 hour post-dose, 'Day 6~Day 11' 0 hour(pre-dose), 'Day 11' 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 48, 72, 96 hour post-dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum observed plasma drug concentration (Cmax)</measure>
    <time_frame>'Day 1' 0(pre-dose), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 48, 72, 96 hour post-dose, 'Day 6~Day 11' 0 hour(pre-dose), 'Day 11' 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 48, 72, 96 hour post-dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under the plasma concentration time-curve (AUC)</measure>
    <time_frame>'Day 1' 0(pre-dose), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 48, 72, 96 hour post-dose, 'Day 6~Day 11' 0 hour(pre-dose), 'Day 11' 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 48, 72, 96 hour post-dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Apparent terminal elimination half-life (t1/2)</measure>
    <time_frame>'Day 1' 0(pre-dose), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 48, 72, 96 hour post-dose, 'Day 6~Day 11' 0 hour(pre-dose), 'Day 11' 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 48, 72, 96 hour post-dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Peak trough fluctuation (PTF)</measure>
    <time_frame>'Day 1' 0(pre-dose), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 48, 72, 96 hour post-dose, 'Day 6~Day 11' 0 hour(pre-dose), 'Day 11' 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 48, 72, 96 hour post-dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Accumulation ratio (R)</measure>
    <time_frame>'Day 1' 0(pre-dose), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 48, 72, 96 hour post-dose, 'Day 6~Day 11' 0 hour(pre-dose), 'Day 11' 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 48, 72, 96 hour post-dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Metabolic ratio</measure>
    <time_frame>'Day 1' 0(pre-dose), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 48, 72, 96 hour post-dose, 'Day 6~Day 11' 0 hour(pre-dose), 'Day 11' 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 48, 72, 96 hour post-dose</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Adverse event</measure>
    <time_frame>Day -1 ~ Day 15</time_frame>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">50</enrollment>
  <condition>Partial-onset Seizures With or Without Secondary Generalisation</condition>
  <arm_group>
    <arm_group_label>Zebinix 400mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo for Zebinix 400mg</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Zebinix 800mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo for Zebinix 800mg</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Zebinix 1600mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo for Zebinix 1600mg</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Zebinix 400mg</intervention_name>
    <description>Zebinix 400mg group is administered with two Zebinix 200mg tablets per day. (Single dose: Day 1, Multiple dose: Day5~11)</description>
    <arm_group_label>Zebinix 400mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo for Zebinix 400mg</intervention_name>
    <description>Placebo for Zebinix 400mg group is administered with two placebo for Zebinix 200mg tablets per day.
(Single dose: Day 1, Multiple dose: Day5~11)</description>
    <arm_group_label>Placebo for Zebinix 400mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Zebinix 800mg</intervention_name>
    <description>Zebinix 800mg group is administered with a Zebinix 800mg tablet per day. (Single dose: Day 1, Multiple dose: Day5~11)</description>
    <arm_group_label>Zebinix 800mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo for Zebinix 800mg</intervention_name>
    <description>Placebo for Zebinix 800mg group is administered with a placebo for Zebinix 800mg tablets per day.
(Single dose: Day 1, Multiple dose: Day5~11)</description>
    <arm_group_label>Placebo for Zebinix 800mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Zebinix 1600mg</intervention_name>
    <description>Zebinix 1600mg group is administered with two Zebinix 800mg tablets per day. (Single dose: Day 1, Multiple dose: Day5~11)</description>
    <arm_group_label>Zebinix 1600mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo for Zebinix 1600mg</intervention_name>
    <description>Placebo for Zebinix 1600mg group is administered with two placebo for Zebinix 800mg tablets per day.
(Single dose: Day 1, Multiple dose: Day5~11)</description>
    <arm_group_label>Placebo for Zebinix 1600mg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy adult volunteers aged 19-45 years at screening

          -  Subjects who weigh more than 50kg with a body mass index(BMI) of 18.0~28.0 kg/m2 at
             screening

          -  Subjects who are fully understood after being given the detailed explanation of this
             clinical trial and willing to give written informed consent for participation prior to
             the screening test

          -  Subjects who are qualified to participate in this clinical trial through the physical
             examination, clinical laboratory test and interview by the investigators

        Exclusion Criteria:

          -  Clinically significant presence or treatment history of cardiovascular, hepatic,
             renal, gastrointestinal, respiratory, neurological, hematological, endocrine,
             psychiatric

          -  Clinically significant surgical history

          -  Clinically significant family history

          -  Clinically significant atopic syndrome

          -  History of hypersensitivity or clinically significant hypersensitivity to drug
             including carbamazepine and related compounds

          -  History of alcoholism or drug abuse or show a positive response to an abuse drug in
             the urine drug screening test

          -  Consistently consume alcohol or cannot stop drinking during the clinical trial

          -  Smoker

          -  Significant infection or inflammatory finding at screening visit

          -  History of gastrointestinal disorders or surgery which may have an effect on the
             safety and pharmacokinetic evaluation of the investigational products (except for
             simple appendectomy and herniotomy)

          -  Have used prescription drugs or herbal medication within 2 weeks of initial
             administration or who have used over the counter(OTC), health functional food or
             vitamins within 1 week of initial administration (but, if the other conditions are
             suitable according to the judgment of the investigator, they can participate in the
             clinical trial), or subjects who have expected to take it

          -  Have participated in any clinical trial (or bioequivalence study) and administered any
             investigational product within 6 months

          -  Positive for HbsAg, anti-HCV and HIV antigen-antibody reaction tests at screening

          -  Have donated any whole blood or apheresis or received blood transfusion within 3
             months of initial administration of this clinical trial

          -  Have dietary restrictions or cannot take the food provided by the institution

          -  Cannot communicate reliably with the investigator

          -  Subjects who are determined by the investigator to be ineligible for participation in
             this clinical trial due to clinical laboratory test results or other reasons
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>In-Jin Jang, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Seoul National University Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Whan In Pharm.</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>September 15, 2019</study_first_submitted>
  <study_first_submitted_qc>September 17, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">September 19, 2019</study_first_posted>
  <last_update_submitted>January 6, 2020</last_update_submitted>
  <last_update_submitted_qc>January 6, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 7, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Seizures</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Eslicarbazepine acetate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

